1. Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial
- Author
-
G.-H. Schernthaner and G. Schernthaner
- Subjects
medicine.medical_specialty ,endocrine system diseases ,Glucose-lowering therapy ,medicine.medical_treatment ,030209 endocrinology & metabolism ,Disease ,Type 2 diabetes ,030204 cardiovascular system & hematology ,Antidiabetische Therapie ,EMPA-REG-Outcome-Studie ,03 medical and health sciences ,0302 clinical medicine ,Diabetes mellitus ,Internal medicine ,Empagliflozin ,EMPA-REG outcome ,Medicine ,Humans ,Hypoglycemic Agents ,PROactive ,Prospective cohort study ,Evidence-Based Medicine ,Kardiovaskuläre Erkrankungen ,Typ-2-Diabetes ,business.industry ,Insulin ,nutritional and metabolic diseases ,Main Topic ,medicine.disease ,Cardiovascular disease ,Surgery ,Metformin ,Treatment Outcome ,Diabetes Mellitus, Type 2 ,Cardiovascular Diseases ,Cardiology and Cardiovascular Medicine ,business ,Pioglitazone ,medicine.drug - Abstract
Prevention of cardiovascular morbidity and mortality remains the key factor in the treatment of type 2 diabetes (T2DM). In the early phase of T2DM, multifactorial intervention is mandatory and glucose levels should be near normal, in particular in younger patients presenting with the highest cardiovascular risk. Anti-diabetic drugs without any risk for hypoglycaemia should be preferred in order to reduce clinical inertia and increase the long-term adherence to the treatment. In patients already presenting with cardiovascular disease, the best outcome may be expected with the triple oral therapy of metformin, pioglitazone, and empagliflozin, although a controlled prospective study versus insulin therapy is needed to confirm the expectation. more...
- Published
- 2016